Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial
about
Prostate cancer treatment: the times they are a' changin'Increasing value and reducing waste: addressing inaccessible researchExpected population impacts of discontinued prostate-specific antigen screening.The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS.The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice.Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000-2009.Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomyThe biology and treatment of oligometastatic cancer.A hospital-based study of initial observation for low-risk prostate cancer and its predictors in the United StatesAge remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based studyTiming of curative treatment for prostate cancer: a systematic review.Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?Active surveillance for clinically localized prostate cancer--a systematic review.Probability of extraprostatic disease according to the percentage of positive biopsy cores in clinically localized prostate cancer.Employment and sick leave in patients with prostate cancer before, during and after radiotherapy.Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort.[Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer.Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancersChanges in preoperative characteristics in patients undergoing radical prostatectomy--a 16-year nationwide analysis.Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources.Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study.Survival outcomes in elderly men undergoing radical prostatectomy in Australia.Active surveillance for localized prostate cancer: update of a prospective single-center cohort.Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects.Radical prostatectomy in high-risk prostate cancer
P2860
Q27025607-59E36DA1-960B-4DEA-8910-C55B35A40968Q28611347-50AA35A6-8399-481F-862C-13247ABE8314Q34458237-E8627E60-71C1-473B-9FD6-4FD0971C5FE7Q34512629-6287F7BB-54D7-4305-B80D-81EA7DF63CD6Q34992168-9A618D5C-6086-40B4-BA74-4F41A3B430C3Q35030034-F05B053E-37FD-4EEC-904C-73B98D315CC8Q35089983-FB2B137C-CEBF-4356-B126-96734F244B91Q35147324-8C90E3E8-722A-461E-ADA6-6E35D5FAE79FQ35188264-802A0D77-226E-4112-A1EE-ACFDAA577B51Q35443808-852560B3-1157-4DC0-A031-70C8905C553CQ35832153-334DF8DB-07EF-454C-A421-2F7A113DFA10Q36414849-E1CE67CD-A136-4E14-A3F4-3CD92A8A7611Q37003387-211ABA1A-120C-4B24-A46A-8AABD40967DEQ37201922-3E2C6FC1-6C6A-41A5-96CF-1FDA881DDA71Q37605565-C172311A-224E-4FE3-B46A-E4B8F329719EQ38151298-A8016E0F-A607-49CC-96DB-982E4AF68113Q38194533-47ACDC60-8E2A-40CF-B084-EE639DB83173Q38392947-C357F6F7-06BF-42ED-B70B-7F556FA42134Q40120521-58DACD7B-4151-4577-B08C-B3BB91A6B1A2Q40216437-DA711D15-80C7-4958-A997-03A1CC29B62EQ40616371-89980913-BD79-4168-83AE-2C9DE6E046CEQ41847374-35C2440B-093F-45D2-8846-08997511EC5BQ42567335-22BF3A98-940E-48AF-A7F5-F63FC9FF212EQ43595827-A966FC52-3E91-4DCC-ACD7-4D94D727DFA3Q44245825-F03D6467-9062-42C9-A1A3-4459500334AAQ44657084-02CEE861-60E4-42C3-A9AB-E3F3274DC8C4Q44847025-85088BE4-F223-4064-B152-4052A63D8392Q47966928-3921D2E4-DEF1-4BB7-9A38-BC592E0B20ABQ48275350-5578E910-F489-4BE5-A40E-3690AC64AD5CQ48282722-4584E29B-10AB-4740-95D6-B53182848928Q55234387-0AFD7031-203A-4705-A6B7-DEC9B6C19D98Q57131976-8FA80C33-997D-45B3-A865-20C075626A3D
P2860
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Individualized estimation of t ...... Cancer Group randomized trial
@ast
Individualized estimation of t ...... Cancer Group randomized trial
@en
type
label
Individualized estimation of t ...... Cancer Group randomized trial
@ast
Individualized estimation of t ...... Cancer Group randomized trial
@en
prefLabel
Individualized estimation of t ...... Cancer Group randomized trial
@ast
Individualized estimation of t ...... Cancer Group randomized trial
@en
P2093
P2860
P50
P1433
P1476
Individualized estimation of t ...... Cancer Group randomized trial
@en
P2093
Anna Bill-Axelson
Caroline Bennette
Jan-Erik Johansson
P2860
P304
P356
10.1016/J.EURURO.2012.04.024
P407
P577
2012-04-19T00:00:00Z